EFSA's Berberine Safety Review: Market Uncertainty, Potential Ban Looms for EU Brands

London, United Kingdom — 31 July 2026

The European Food Safety Authority (EFSA) has concluded its initial assessment of berberine, stating it cannot determine a safe intake level for the botanical. This finding, published earlier this year, has prompted a formal consultation period to define berberine's future regulatory status within the European Union. The outcome of this consultation is critical, as it could lead to significant restrictions on its use in food supplements, or even a complete market ban.

Berberine, commonly sourced from plants like Berberis Vulgaris (European Barberry), has seen increasing popularity in the supplement sector. However, EFSA's draft opinion, first highlighted in March 2026, has cast a shadow over its commercial viability. The absence of a definitive safe intake level puts the onus on brand owners and manufacturers to demonstrate product safety in a market increasingly scrutinised by regulators.

Industry experts anticipate that the consultation process will conclude by late 2026, with any subsequent regulatory changes likely to be implemented within 2027. This timeline allows a narrow window for manufacturers to adapt their product portfolios. Companies currently utilising berberine as a key ingredient must now prioritise contingency planning, including sourcing alternative active compounds or preparing for product discontinuation. The precedent set by EFSA in similar cases suggests a high probability of either a maximum daily dose restriction or a complete prohibition, depending on the scientific data submitted during the consultation phase.

What this means for the United Kingdom

UK supplement brand owners and manufacturers must closely monitor EFSA's final decision, as it frequently influences MHRA and FSA policy, particularly for novel botanicals. While the UK is no longer bound by EU law, the 'no safe intake' conclusion presents a significant risk for parallel regulatory action. Businesses should audit existing berberine product lines, assess reformulation costs, and engage with ingredient suppliers to understand potential lead time extensions for alternative compounds. Proactive engagement with UK regulatory bodies is advisable to anticipate domestic policy shifts and manage competitive positioning in a market where consumer safety concerns are paramount.

The financial implications for businesses operating in the EU are substantial. Reformulation cycles typically incur development costs ranging from €20,000 to €100,000 per product, alongside potential delays in market entry for new SKUs. Brand owners with established berberine-containing products must evaluate the cost-benefit of defending the ingredient's safety through additional data submission versus pivoting to alternative formulations. Furthermore, the reputational risk associated with products that become subject to regulatory warnings cannot be understated.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.